Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025. Stamoulis, currently the EVP and Chief Financial Officer of Incyte, will succeed Bryan Reasons, who has decided to leave the company to pursue other interests.

Stamoulis joins Mallinckrodt from Incyte, a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. In addition to overseeing the finance organization, she will lead Mallinckrodt’s corporate development initiatives, leveraging her industry expertise and extensive experience in strategic planning, as well as in originating, structuring, and executing strategic partnerships and M&A transactions.

Stamoulis has roughly 30 years of experience in the biotechnology industry. Before Incyte, she was President and CFO of Unum Therapeutics and, before that role, served as Senior Vice President of Corporate Strategy and Business Development at Vertex Pharmaceuticals. 

Before Vertex, Stamoulis spent nearly 15 years as an investment banker and management consultant, serving as a Managing Director in Citigroup’s Investment Banking division and a senior investment banker in the Healthcare Investment Banking Group at Goldman Sachs. 

Siggi Olafsson, Mallinckrodt’s President and Chief Executive Officer, said, “With the completion last week of our merger with Endo, we are forging a new future for our Company and adding talented new leadership to an already strong executive team. Christiana has an exceptional record of achievement in strategy, finance, corporate development, and execution, and we have every expectation that she will make significant contributions to our growth and continued success.”